Last reviewed · How we verify
Bevacizumab and trastuzumab maintenance therapy
Bevacizumab and trastuzumab maintenance therapy is a Antibody-drug conjugate Small molecule drug developed by Sanofi. It is currently in Phase 2 development for Breast cancer, Non-small cell lung cancer. Also known as: Avastin® (bevacizumab), Herceptin® (trastuzumab).
Inhibits vascular endothelial growth factor A (VEGFA) and human epidermal growth factor receptor 2 (HER2)
Inhibits vascular endothelial growth factor A (VEGFA) and human epidermal growth factor receptor 2 (HER2) Used for Breast cancer, Non-small cell lung cancer.
At a glance
| Generic name | Bevacizumab and trastuzumab maintenance therapy |
|---|---|
| Also known as | Avastin® (bevacizumab), Herceptin® (trastuzumab) |
| Sponsor | Sanofi |
| Drug class | Antibody-drug conjugate |
| Target | VEGFA, HER2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bevacizumab is a recombinant humanized monoclonal antibody that binds to VEGFA, preventing its interaction with its receptors. Trastuzumab is a recombinant humanized monoclonal antibody that binds to HER2, preventing its interaction with downstream signaling pathways.
Approved indications
- Breast cancer
- Non-small cell lung cancer
Common side effects
- Hypertension
- Nausea
- Fatigue
- Headache
- Diarrhea
Key clinical trials
- Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) (PHASE3)
- Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU (PHASE3)
- Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (PHASE1, PHASE2)
- A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (PHASE2)
- Bevacizumab in Multiple Phase I Combinations (PHASE1)
- Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients (PHASE2)
- A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer (PHASE2)
- Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab and trastuzumab maintenance therapy CI brief — competitive landscape report
- Bevacizumab and trastuzumab maintenance therapy updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Bevacizumab and trastuzumab maintenance therapy
What is Bevacizumab and trastuzumab maintenance therapy?
How does Bevacizumab and trastuzumab maintenance therapy work?
What is Bevacizumab and trastuzumab maintenance therapy used for?
Who makes Bevacizumab and trastuzumab maintenance therapy?
Is Bevacizumab and trastuzumab maintenance therapy also known as anything else?
What drug class is Bevacizumab and trastuzumab maintenance therapy in?
What development phase is Bevacizumab and trastuzumab maintenance therapy in?
What are the side effects of Bevacizumab and trastuzumab maintenance therapy?
What does Bevacizumab and trastuzumab maintenance therapy target?
Related
- Drug class: All Antibody-drug conjugate drugs
- Target: All drugs targeting VEGFA, HER2
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer
- Indication: Drugs for Non-small cell lung cancer
- Also known as: Avastin® (bevacizumab), Herceptin® (trastuzumab)
- Compare: Bevacizumab and trastuzumab maintenance therapy vs similar drugs
- Pricing: Bevacizumab and trastuzumab maintenance therapy cost, discount & access